{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:28Z","timestamp":1793982268570,"version":"4.8.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101328","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:16:10Z","timestamp":1754424970000},"page":"101328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia"],"prefix":"10.1016","volume":"74","author":[{"given":"Bruno","family":"Fattizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona E.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.blre.2025.101328_bb0005","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of autoimmune diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.blre.2025.101328_bb0015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3324\/haematol.2014.114561","article-title":"Treatment of autoimmune hemolytic anemias","volume":"99","author":"Zanella","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101328_bb0020","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.thromres.2015.09.004","article-title":"Autoimmune hemolytic anemia and venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Ungprasert","year":"2015","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14740\/jh303w","article-title":"Warm autoimmune hemolytic anemia: clinical profile and management","volume":"6","author":"Sudulagunta","year":"2017","journal-title":"J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2025.101328_bb0035","first-page":"1160","article-title":"Autoimmune hemolytic anemia confers an independent risk factor for thrombosis: retrospective cohort study using the \u201cSTRIDE\u201d database","volume":"4","author":"Chen","year":"2017","journal-title":"Ann Hematol Oncol"},{"issue":"11","key":"10.1016\/j.blre.2025.101328_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207218","article-title":"Venous thromboembolic events during warm autoimmune hemolytic anemia","volume":"13","author":"Audia","year":"2018","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.blre.2025.101328_bb0045","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15757","article-title":"Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia","volume":"20","author":"Fattizzo","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0050","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/pharmaceutics14051035","article-title":"Development of new drugs for autoimmune hemolytic anemia","volume":"14","author":"Xiao","year":"2022","journal-title":"Pharmaceutics"},{"issue":"15","key":"10.1016\/j.blre.2025.101328_bb0055","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101328_bb0060","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00002018-200730010-00004","article-title":"Drug-induced musculoskeletal disorders","volume":"30","author":"Bannwarth","year":"2007","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2310\/6620.2006.05047","article-title":"Cutaneous reactions to injectable corticosteroids","volume":"17","author":"Amin","year":"2006","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/fcp.12247","article-title":"Drug-induced progressive multifocal leukoencephalopathy: a case\/noncase study in the French PharmacoVigilance database","volume":"31","author":"Colin","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1076\/ocii.6.3.185.4040","article-title":"Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids","volume":"6","author":"Satoh","year":"1998","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"10.1016\/j.blre.2025.101328_bb0085","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2165\/00002512-200825090-00005","article-title":"Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort","volume":"25","author":"Feng","year":"2008","journal-title":"Drugs Aging"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0090","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1440-1819.2011.02260.x","article-title":"Psychiatric complications of treatment with corticosteroids: review with case report","volume":"65","author":"Kenna","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2025.101328_bb0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: causes and consequences","volume":"18","author":"Fattizzo","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.blre.2025.101328_bb0105","doi-asserted-by":"crossref","unstructured":"Gonzalez-Lopez T.J., Provan D. The new era of primary immune thrombocytopenia management in adults: a narrative review of current and emerging treatments. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2025.101300, Epub ahead of print.","DOI":"10.1016\/j.blre.2025.101300"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","article-title":"Autoimmune haemolytic anaemias","volume":"10","author":"Michel","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12026-014-8497-0","article-title":"Haemoglobin levels in autoimmune haemolytic anaemias at diagnosis: relationship with immunoproteins on red blood cells","volume":"60","author":"Lai","year":"2014","journal-title":"Immunol Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000439002","article-title":"New insights in the pathogenesis of autoimmune hemolytic Anemia","volume":"42","author":"Barcellini","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.blre.2025.101328_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0135","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1159\/000488753","article-title":"A comprehensive diagnostic algorithm for direct antiglobulin test-negative autoimmune hemolytic anemia reveals the relative ratio of three mechanisms in a single laboratory","volume":"140","author":"Kamesaki","year":"2018","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.hoc.2021.11.004","article-title":"DAT-negative autoimmune hemolytic anemia","volume":"36","author":"Rodberg","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"10.1016\/j.blre.2025.101328_bb0145","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101328_bb0150","series-title":"Reference guide for the diagnosis and treatment of autoimmune hemolytic anemia. Revised edition of 2019","author":"Harigai","year":"2020"},{"issue":"9","key":"10.1016\/j.blre.2025.101328_bb0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1309\/LMTPWB8ZNJYEG9AR","article-title":"Significance of quantitation of autoantibodies in the eluate of sensitized red cells in warm autoimmune hemolytic anemia","volume":"40","author":"Chaudhary","year":"2009","journal-title":"Lab Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0160","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00277-004-0959-3","article-title":"Characterization of red cell autoantibodies in consecutive DAT-positive patients with relation to in vivo haemolysis","volume":"84","author":"Wikman","year":"2005","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0165","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ajcp\/79.2.182","article-title":"The enzyme-linked immunosorbent assay: accurate detection of red blood cell antibodies in autoimmune hemolytic anemia","volume":"79","author":"Bodensteiner","year":"1983","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0170","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1537-2995.1993.33693296807.x","article-title":"Quantitation of immunoglobulin classes and subclasses of autoantibodies bound to red cells in patients with and without hemolysis","volume":"33","author":"Dubarry","year":"1993","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.blre.2025.101328_bb0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2257.2006.00798.x","article-title":"Quantitation of red cell-bound IgG by an enzyme-linked antiglobulin test in the patients with warm-type autoimmune haemolytic anaemia","volume":"28","author":"Fabijanska-Mitek","year":"2006","journal-title":"Clin Lab Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ajh.21336","article-title":"Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia","volume":"84","author":"Kamesaki","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1055\/s-0041-1741442","article-title":"A study of clinical and serological correlation of positive direct antiglobulin test in blood bank at a tertiary care center","volume":"14","author":"Kerkar","year":"2022","journal-title":"J Lab Physicians"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2022.103492","article-title":"Influence of immunohematological markers on severity of in vivo hemolysis in human warm autoimmune haemolytic anemia","volume":"61","author":"Das","year":"2022","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.blre.2025.101328_bb0195","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0200","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0002-9343(81)90337-5","article-title":"Specific immunoadsorption of IgG antibody in a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. A new form of therapy for the acute critical stage","volume":"71","author":"Besa","year":"1981","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101328_bb0205","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1046\/j.1537-2995.2002.00193.x","article-title":"Durable response to combination therapy including staphylococcal protein a immunoadsorption in life-threatening refractory autoimmune hemolysis","volume":"42","author":"Javeed","year":"2002","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.blre.2025.101328_bb0210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jca.21790","article-title":"Efficacy of therapeutic plasma exchange for treatment of autoimmune hemolytic anemia: a systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Deng","year":"2020","journal-title":"J Clin Apher"},{"issue":"12","key":"10.1016\/j.blre.2025.101328_bb0215","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/intimm\/2.12.1133","article-title":"Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanisms","volume":"2","author":"Shibata","year":"1990","journal-title":"Int Immunol"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0220","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOH.0000000000000459","article-title":"Murine models of autoimmune hemolytic anemia","volume":"25","author":"Howie","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jvim.15441","article-title":"ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats","volume":"33","author":"Garden","year":"2019","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.blre.2025.101328_bb0230","article-title":"Canine immune-mediated hemolytic anemia \u2013 brief review. Tradit Mod","volume":"3(No 1(4)):59-64","author":"Manev","year":"2018","journal-title":"Vet Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0235","first-page":"190","article-title":"Isotype-specific antibodies in horses and dogs with immune-mediated hemolytic anemia","volume":"14","author":"Wilkerson","year":"2000","journal-title":"J Vet Int Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0240","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.V41.2.293.293","article-title":"Autoimmune hemolytic anemia during pregnancy with hemolytic disease in the newborn","volume":"41","author":"Baumann","year":"1973","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0245","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2141.1973.tb05742.x","article-title":"Pregnancy and idiopathic autoimmune haemolytic anaemia: a prospective study during 6 months gestation and 3 months post-partum","volume":"24","author":"Chaplin","year":"1973","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101328_bb0250","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1055\/s-0035-1558131","article-title":"Pregnancy induced autoimmune warm antibodies hemolytic anemia: a case report","volume":"75","author":"Lauzikiene","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0255","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.1537-2995.1982.22182154222.x","article-title":"Successful exchange transfusion of an infant for AIHA developing late in mother\u2019s pregnancy","volume":"22","author":"Lawe","year":"1982","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.blre.2025.101328_bb0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1423-0410.1982.tb00008.x","article-title":"Erythrocyte autoantibodies, autoimmune haemolysis and pregnancy","volume":"43","author":"Sokol","year":"1982","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0265","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0270","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"issue":"17","key":"10.1016\/j.blre.2025.101328_bb0280","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.blre.2025.101328_bb0285","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.blre.2025.101328_bb0290","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.blre.2025.101328_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.04.031","article-title":"Safety, tolerability, and activity of ALXN1830 targeting the neonatal Fc receptor in chronic pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0300","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.blre.2025.101328_bb0305","article-title":"Serum autoantibody lowering by the anti-FcRn monoclonal antibody, nipocalimab, correlates with clinical improvement in generalized myasthenia gravis patients","volume":"99(23 Supplement 2):S35-7","author":"Ramchandren","year":"2022","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.blre.2025.101328_bb0310","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2025.101328_bb0315","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0320","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02786322","article-title":"Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG","volume":"16","author":"Junghans","year":"1997","journal-title":"Immunol Res"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0325","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.blre.2025.101328_bb0330","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0810796106","article-title":"Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice","volume":"106","author":"Montoyo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0335","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/19420862.2019.1602459","article-title":"Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis","volume":"11","author":"Challa","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.blre.2025.101328_bb0340","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0345","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/uog.24891","article-title":"Targeting neonatal Fc receptor: potential clinical applications in pregnancy","volume":"60","author":"Moise","year":"2022","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.blre.2025.101328_bb0350","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","article-title":"Structural insights into neonatal Fc receptor-based recycling mechanisms","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.blre.2025.101328_bb0355","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176166","article-title":"Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin","volume":"9","author":"Ma","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2025.101328_bb0360","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphys.2017.00149","article-title":"Analysis of a compartmental model of endogenous immunoglobulin g metabolism with application to multiple myeloma","volume":"8","author":"Kendrick","year":"2017","journal-title":"Front Physiol"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0365","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/mabs.25439","article-title":"Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis","volume":"5","author":"Challa","year":"2013","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.blre.2025.101328_bb0370","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0375","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1003780","article-title":"Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model","volume":"187","author":"Patel","year":"2011","journal-title":"J Immunol"},{"issue":"18","key":"10.1016\/j.blre.2025.101328_bb0380","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1182\/blood-2010-05-284919","article-title":"Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0385","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1681\/ASN.2013050498","article-title":"Neonatal Fc receptor promotes immune complex-mediated glomerular disease","volume":"25","author":"Olaru","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2025.101328_bb0390","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.blre.2025.101328_bb0395","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.blre.2025.101328_bb0400","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0405","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"issue":"21","key":"10.1016\/j.blre.2025.101328_bb0410","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis","volume":"297","author":"Dau","year":"1977","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2025.101328_bb0415","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9(414):eaan1208","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101328_bb0420","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.iac.2008.07.001","article-title":"Immunoglobulin replacement therapy in children","volume":"28","author":"Garcia-Lloret","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.blre.2025.101328_bb0425","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaip.2015.11.034","article-title":"Risk factors and clinical significance of lymphopenia in survivors of the Fontan procedure for single-ventricle congenital cardiac disease","volume":"4","author":"Morsheimer","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0430","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1172\/JCI114947","article-title":"Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin","volume":"86","author":"Waldmann","year":"1990","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.blre.2025.101328_bb0435","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/rheumatology\/40.5.513","article-title":"Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?","volume":"40","author":"Schmaldienst","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.blre.2025.101328_bb0440","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2025.101328_bb0445","doi-asserted-by":"crossref","first-page":"1302714","DOI":"10.3389\/fnins.2024.1302714","article-title":"Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study","volume":"18","author":"Leu","year":"2024","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0450","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.blre.2025.101328_bb0455","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn","volume":"391","author":"Moise","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2025.101328_bb0460","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","article-title":"Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren\u2019s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS)","volume":"83","author":"Gottenberg","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0470","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol Ther"},{"issue":"15 Supplement","key":"10.1016\/j.blre.2025.101328_bb0475","article-title":"RVT-1401, a novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration (P5.2-079)","volume":"92","author":"Collins","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0480","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.19858","article-title":"Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","volume":"206","author":"Cooper","year":"2025","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101328_bb0485","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.blre.2025.101328_bb0490","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40261-024-01380-0","article-title":"Pharmacokinetics and pharmacodynamics of nipocalimab, a neonatal Fc receptor blocker, in healthy Japanese volunteers","volume":"44","author":"Matsushima","year":"2024","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.blre.2025.101328_bb0495","doi-asserted-by":"crossref","first-page":"2461191","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.blre.2025.101328_bb0500","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.blre.2025.101328_bb0505","series-title":"VYVGART \u2122 (efgartigimod alfa-fcab) injection [package insert]","year":"2021"},{"key":"10.1016\/j.blre.2025.101328_bb0510","series-title":"VYVGART\u00ae HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) [package insert]","year":"2023"},{"key":"10.1016\/j.blre.2025.101328_bb0515","series-title":"RYSTIGGO\u00ae (rozanolixizumab-noli) [package insert]","year":"2023"},{"key":"10.1016\/j.blre.2025.101328_bb0520","series-title":"IMAAVY\u2122 (nipocalimab-aahu) injection, for intravenous use [patient information]","year":"2025"},{"key":"10.1016\/j.blre.2025.101328_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.637336","article-title":"A systematic review and meta-analysis of autoantibodies for diagnosis and prognosis in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Guo","year":"2021","journal-title":"Front Neurosci"},{"issue":"10","key":"10.1016\/j.blre.2025.101328_bb0530","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"New Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101328_bb0535","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2022-167838","article-title":"Efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia: results of a phase 3, multicenter, double-blinded, placebo-controlled, randomized clinical trial (ADVANCE IV)","volume":"140","author":"Broome","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101328_bb0540","first-page":"842","article-title":"Design of a phase 3, global, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn","volume":"42","author":"Komatsu","year":"2024","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.blre.2025.101328_bb0545","article-title":"Design of a phase 3, multicenter, randomized, open-label study of nipocalimab or IVIG in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia (FREESIA-3)","volume":"144(Supplement 1):1193.1","author":"Bussel","year":"2024","journal-title":"Blood"},{"issue":"Supplement 9","key":"10.1016\/j.blre.2025.101328_bb0550","first-page":"1988","article-title":"A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants","volume":"76","author":"Cossu","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.blre.2025.101328_bb0555","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"10.1016\/j.blre.2025.101328_bb0560","article-title":"Post-hoc analysis of clinically relevant anti-vaccine antibodies in participants with rheumatoid arthritis treated with nipocalimab. Arthritis","volume":"76(Supplement 9):1978.5","author":"Yu","year":"2024","journal-title":"Rheumatol"},{"key":"10.1016\/j.blre.2025.101328_bb0565","series-title":"Poster presented at American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, September 21-24, 2022, Nashville, TN, USA","article-title":"Pharmacokinetic drug interaction between nipocalimab and fremanezumab in healthy subjects","author":"Bei","year":"2022"},{"issue":"Supplement 2","key":"10.1016\/j.blre.2025.101328_bb0570","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.htct.2022.09.019","article-title":"Efficacy and safety of nipocalimab, an FcRn blocker, in warm autoimmune hemolytic anemia (wAIHA): ENERGY phase 2\/3 study design","volume":"44","author":"Murakhovskaya","year":"2022","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.blre.2025.101328_bb0575","unstructured":"Immunovant reports financial results and recent business updates for the quarter ended December 31, 2022. Accessed July 21, 2023."},{"key":"10.1016\/j.blre.2025.101328_bb0580","unstructured":"Alexion. Alexion reports first quarter 2021 results. https:\/\/media.alexion.com\/news-releases\/news-release-details\/alexion-reports-first-quarter-2021-results. Accessed July 21, 2023."},{"issue":"10","key":"10.1016\/j.blre.2025.101328_bb0585","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.blre.2025.101328_bb0590","author":"argenyx."},{"key":"10.1016\/j.blre.2025.101328_bb0595","author":"argenyx."},{"issue":"9","key":"10.1016\/j.blre.2025.101328_bb0600","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jnnp-2023-333112","article-title":"Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study","volume":"95","author":"Querol","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.blre.2025.101328_bb0605","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.blre.2025.101328_bb0610","author":"Court of the Chancery of the State of Delaware"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:32:03Z","timestamp":1766079123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":122,"alternative-id":["S0268960X25000736"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101328","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101328"}}